Calcified Tissue International

, Volume 63, Issue 2, pp 93–97

Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis

  • Dere W. 
  • B. Avouac
  • M. Boers
  • M. Buxton
  • C. Christiansen
  • A. Dawson
  • C. Gennari
  • F. Guillemin
  • H. Lawetz
  • F. Ornskov
  • I. Roumagnac
  • J. Y. Reginster
Editorial

DOI: 10.1007/BF03322783

Cite this article as:
Dere, W., Avouac, B., Boers, M. et al. Calcif Tissue Int (1998) 63: 93. doi:10.1007/BF03322783

Copyright information

© Springer-Verlag New York Inc. 1998

Authors and Affiliations

  • Dere W. 
    • 1
  • B. Avouac
    • 2
  • M. Boers
    • 3
  • M. Buxton
    • 4
  • C. Christiansen
    • 5
  • A. Dawson
    • 6
  • C. Gennari
    • 7
  • F. Guillemin
    • 8
  • H. Lawetz
    • 5
  • F. Ornskov
    • 9
  • I. Roumagnac
    • 10
  • J. Y. Reginster
    • 11
  1. 1.Diabetes Care & Endocrinology, Lilly Research LaboratoriesEli Lilly & Company, Lilly Corporate CentreIndianapolisUSA
  2. 2.Hospital Henri MondorCreteilFrance
  3. 3.Department of Internal Medicine/RheumatologyUniversity of MaastrichtNederlands
  4. 4.Health Economics Research Group, BrunelThe University of West LondonUxbirdge, MiddlesexUK
  5. 5.Center for Clinical & Basic ResearchBallerupDenmark
  6. 6.Eli Lilly & Company Ltd.Lilly Research CentreErl Wood Manor, Windlesham, SurreyUK
  7. 7.Ospedale Santa Maria della ScaleSiennaItaly
  8. 8.Faculty of MedicineSchool of Public HealthNancyFrance
  9. 9.Merck & Co., Inc.West PointUSA
  10. 10.Proctor and Gamble PharmaceuticalsStaines, MiddlesexUK
  11. 11.Policliniques L. Brull, Service de Metabolisme OsseuxLiegeBelgium